PharmaClik Login 
Pharmacists are highly trained healthcare professionals who play a vital role in the management of patients' health, including the prescribing of medications. Pharmacist prescribing authority – their ability to prescribe medications, initiate and adjust doses, and manage drug therapeutic substitutions for patients without the need for physician involvement – has been an ongoing topic of policy discussions across all Canadian provinces in the aftermath of the COVID-19 pandemic. Expanding prescribing authority to pharmacists’ full capabilities across all provinces has never been more urgent and relevant than in this period of severe, enduring healthcare professional shortage across the country.
McKesson Corporation Completes Divestiture of Canada-Based Rexall and Well.ca Businesses - McKesson Canada
Press Releases
Stay Informed with Our Latest Healthcare Updates and Announcements
Press Releases
Stay Informed with Our Latest Healthcare Updates and Announcements
December 31, 2024 (IRVING, Texas) – McKesson Corporation (NYSE: MCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This transaction enables the Company to focus capital deployment and prioritize investments expanding its strategic oncology and biopharma growth platforms.
Additional details related to the divestiture can be found on the company’s Investor Relations website.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
Cautionary Statements
Except for historical information, statements in this press release regarding McKesson’s capital deployment, investment and growth platforms constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in the company’s most recent Form 10-K filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: we may be unsuccessful in achieving our strategic growth objectives; our use of third-party data is subject to limitations that could impede the growth of our data services business; we might be adversely impacted by changes in the economic environments in which we operate; and we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events.
Contacts
Investor Relations
Rachel Rodriguez
469-260-2556
Rachel.Rodriguez@McKesson.com
Media
Media@mckesson.ca
A significant public policy priority for the Government of Canada is ensuring comprehensive, timely, and equitable access to medication for rare diseases; as such, the Government of Canada has allocated $500 million annually to a national strategy for rare disease drugs. McKesson Canada is proud to contribute to this conversation, drawing on experience with patient support programs, pharmaceutical distribution, and specialty pharmacy services.
The Government of Canada would like to develop a solution to ensure universal drug coverage for Canadians. This solution would mean all Canadians would have access to a comprehensive, affordable drug insurance plan regardless of their province of residence or financial situation. Where the coverage comes from is an important consideration, but what ultimately matters is that all Canadians can acquire the medicine they need regardless of their particular financial, geographic or health circumstances.
